The Monster Business Lurking Behind Fulgent's COVID Results
Like many companies, Fulgent Genetics (NASDAQ: FLGT) has been labeled a "pandemic stock" by some investors. In the most recent quarter, 82% of Fulgent's revenue came from COVID-19 tests. In the most recent quarter, Fulgent's revenue grew to $126 million, a 124% increase over the third quarter of 2020.